相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study
Takeshi Hatanaka et al.
ONCOLOGY (2021)
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression
Atsushi Hiraoka et al.
HEPATOLOGY RESEARCH (2021)
The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
Kaoru Tsuchiya et al.
CANCERS (2021)
Association of Albumin-Bilirubin Grade and Sequential Treatment with Standard Systemic Therapies for Advanced Hepatocellular Carcinoma: A Retrospective Cohort Study Using a Japanese Administrative Database
Atsushi Hiraoka et al.
DRUGS-REAL WORLD OUTCOMES (2021)
Neutrophil-to-lymphocyte ratio is associated with survival in patients with unresectable hepatocellular carcinoma treated with lenvatinib
Toshifumi Tada et al.
LIVER INTERNATIONAL (2020)
The Processing, Gene Regulation, Biological Functions, and Clinical Relevance of N4-Acetylcytidine on RNA: A Systematic Review
Gehui Jin et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Changes in Background Liver Function in Patients with Hepatocellular Carcinoma over 30 Years: Comparison of Child-Pugh Classification and Albumin Bilirubin Grade
Takashi Kumada et al.
LIVER CANCER (2020)
LEPR hypomethylation is significantly associated with gastric cancer in males
Hang Yu et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2020)
Analysis of Post-Progression Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib
Yuwa Ando et al.
ONCOLOGY (2020)
Predicting outcomes for recurrent hepatocellular carcinoma within Milan criteria after complete radiofrequency ablation
Hsin-Yeh Chen et al.
PLOS ONE (2020)
Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: Multicenter analysis
Atsushi Hiraoka et al.
HEPATOLOGY RESEARCH (2019)
Impact of Baseline ALBI Grade on the Outcomes of Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Multicenter Study
Kazuomi Ueshima et al.
CANCERS (2019)
Immunodeficiency Promotes Adaptive Alterations of Host Gut Microbiome: An Observational Metagenomic Study in Mice
Shuyu Zheng et al.
FRONTIERS IN MICROBIOLOGY (2019)
Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic
Toshifumi Tada et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2019)
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
Jorge A. Marrero et al.
HEPATOLOGY (2018)
Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase III RESORCE trial
Richard S. Finn et al.
JOURNAL OF HEPATOLOGY (2018)
The role of molecular enrichment on future therapies in hepatocellular carcinoma
Jean-Charles Nault et al.
JOURNAL OF HEPATOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
Atsushi Hiraoka et al.
LIVER CANCER (2017)
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications
Atsushi Hiraoka et al.
LIVER CANCER (2017)
Evidence-based Clinical Practice Guidelines for Hepatocellular Carcinoma: The Japan Society of Hepatology 2013 update (3rd JSH-HCC Guidelines)
Norihiro Kokudo et al.
HEPATOLOGY RESEARCH (2015)
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach-The ALBI Grade
Philip J. Johnson et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
EASL–EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma
et al.
JOURNAL OF HEPATOLOGY (2015)
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
Masatoshi Kudo et al.
LIVER CANCER (2014)
Investigation of the freely available easy-to-use software 'EZR' for medical statistics
Y. Kanda
BONE MARROW TRANSPLANTATION (2013)
Epidemiology and Surveillance of Hepatocellular Carcinoma
Do Young Kim et al.
LIVER CANCER (2012)
Management of Hepatocellular Carcinoma: An Update
Jordi Bruix et al.
HEPATOLOGY (2011)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
Ann-Lii Cheng et al.
LANCET ONCOLOGY (2009)
Management of hepatoceullular carcinoma
J Bruix et al.
HEPATOLOGY (2005)
Survival model predictive accuracy and ROC curves
PJ Heagerty et al.
BIOMETRICS (2005)
分享论文
